Revvity (NYSE:RVTY) Price Target Raised to $105.00 at Barclays

Revvity (NYSE:RVTY) had its price target hoisted by Barclays from $95.00 to $105.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

RVTY has been the subject of several other reports. Robert W. Baird set a $117.00 price objective on Revvity in a report on Wednesday. Evercore increased their price objective on Revvity from $112.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. The Goldman Sachs Group cut their price objective on Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a report on Tuesday, April 14th. JPMorgan Chase & Co. cut their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Stifel Nicolaus cut their target price on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a report on Wednesday. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $107.73.

Revvity Stock Up 2.4%

Shares of NYSE:RVTY traded up $2.42 during midday trading on Thursday, hitting $101.27. 1,536,314 shares of the stock were exchanged, compared to its average volume of 1,302,734. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.40 and a current ratio of 1.72. Revvity has a 52-week low of $81.22 and a 52-week high of $118.30. The business’s fifty day simple moving average is $90.30 and its two-hundred day simple moving average is $96.90. The company has a market capitalization of $11.32 billion, a PE ratio of 48.55, a P/E/G ratio of 2.13 and a beta of 1.05.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The business had revenue of $711.12 million during the quarter, compared to analyst estimates of $704.07 million. During the same period last year, the company earned $1.01 earnings per share. Revvity’s quarterly revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, research analysts predict that Revvity will post 5.33 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be paid a $0.07 dividend. The ex-dividend date is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s payout ratio is presently 13.40%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RVTY. Ascentis Independent Advisors bought a new position in Revvity in the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC bought a new position in Revvity in the 2nd quarter worth approximately $32,000. Cromwell Holdings LLC increased its position in Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after buying an additional 198 shares during the period. MUFG Securities EMEA plc bought a new position in Revvity in the 2nd quarter worth approximately $34,000. Finally, SJS Investment Consulting Inc. increased its position in Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after buying an additional 521 shares during the period. 86.65% of the stock is owned by institutional investors.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.